Table 2.
Normalized | Persistently abnormal | P values | |||
---|---|---|---|---|---|
n = 35 | n = 52 | ||||
Male sex, n (%) | 25 | ( 71 ) | 39 | ( 75 ) | 0.7 |
Follow-up years* | 8.3 | (6.8 - 9.6) | 6.8 | (3.4 - 8.6) | |
Age at diagnosis* | 43 | (33 - 51) | 45 | (33 - 52) | 0.98 |
Symptomatic at diagnosis, n (%) | 18 | ( 51 ) | 19 | ( 37 ) | 0.16 |
Inflammatory bowel disease, n (%) | 28 | ( 80 ) | 38 | ( 73 ) | 0.45 |
Biopsy at diagnosis, n (%) | 26 | ( 74 ) | 39 | ( 75 ) | 0.94 |
Biopsy stage* | 1 | (1- 2) | 2 | (2 - 3) | <0.01 |
Laboratory values: | |||||
Alkaline phosphatase (ULN ratio)* | 2 | (1.1 - 3.2) | 3.4 | (2.4 - 5) | <0.01 |
AST (U/L)* | 47 | (33 - 100) | 102 | (60 - 140) | <0.01 |
Total bilirubin (mg/dL)* | 0.8 | (0.6 - 1.5) | 1.2 | (0.8 - 2.2) | 0.04 |
INR* | 1 | (0.9 - 1) | 1 | (0.9 - 1.1) | 0.41 |
Albumin (g/dL)* | 4.1 | (3.8 - 4.4) | 3.9 | (3.6 - 4.2) | 0.13 |
Initial MELD score* | 8 | (6 - 9) | 8 | (7 - 11) | 0.16 |
Initial Mayo risk score* | 0 | (0 - 0.4) | 0.41 | (0 - 1.07) | <0.01 |
Treated with UDCA, n (%) | 18 | ( 51 ) | 29 | ( 56 ) | 0.69 |
Treated with high dose UDCA#, n (%) | 5 | ( 14 ) | 7 | ( 13 ) | 0.78 |
Treated with stricture dilatation, n (%) | 15 | ( 43 ) | 30 | ( 58 ) | 0.17 |
AST, aspartate aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
Median with inter-quartile range included parenthetically.
High dose UDCA was dosing greater than 25 mg/kg.